★ Analysts see FY2027 revenue reaching $160.6B — +12.5% growth in a single year.
What Moves the Stock
01Domestic formulations growth rate relative to Indian Pharma Market (IPM) growth of 8-10%, driven by prescription volume trends and new product launches
02Gross margin trajectory based on API input costs (particularly Chinese API prices) and product mix shift toward higher-margin chronic therapies
03Market share gains in key therapeutic segments (cardiovascular 5.2%, anti-diabetic 4.8% current share) versus competitors like Sun Pharma, Cipla, Dr. Reddy's
04Regulatory actions by Indian drug pricing authority (NPPA) affecting price controls on essential medicines comprising 20-25% of portfolio
05Field force productivity metrics and rural market penetration expansion beyond current 60% coverage
06Branded generics in Indian domestic market (~85% of revenue): cardiovascular, anti-diabetic, respiratory, gastro-intestinal segments
07Consumer healthcare products (~10% of revenue): condoms, antacid tablets, pregnancy detection kits under Manforce and Prega News brands
08Export formulations (~5% of revenue): regulated and semi-regulated markets including Africa, Asia-Pacific
growth - Investors are attracted to 18% revenue growth significantly above Indian pharma market growth, strong domestic market positioning…
Rising interest rates have minimal direct impact on operations given low debt levels (0.55x D/E) and limited borrowing requirements…
Watch on earnings: Indian Pharmaceutical Market (IPM) growth rate published monthly by IQVIA/AIOCD tracking 8-10% baseline growth, USD/INR exchange rate (DEXINUS) affecting API import costs from China representing 15-20% of raw material spend, Chinese API price indices for key molecules (cardiovascular, anti-diabetic APIs) impacting gross margins with 3-6 month lag.
One Sentence Summary:
Mankind Pharma: the story is balanced — domestic formulations growth rate relative to indian pharma market (ipm) growth of 8-10%.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
